HIROKAZU NAGAI

Profile Information

Affiliation: National Hospital Organization Nagoya Medical Center

Researcher number: 30360811
J-GLOBAL ID: 201801017860598459
researchmap Member ID: B000307843

Research Interests

Research Areas

Life sciences / Hematology and oncology /

Research History

- Present

Directror, Department of Hematology/Oncology Rearch, National Hospital Organization Nagoya Medical Center

Education

- Present

school of medicine, Kanazawa University

Papers

142

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.

Takashi Watanabe, Yoshihiro Matsuno, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando …

Hematological oncology, 42(3) e3272, May, 2024
<scp>R‐CHOP</scp> treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of <scp>JCOG0203</scp>

Takashi Watanabe, Kensei Tobinai, Masaki Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando …

British Journal of Haematology, Nov 23, 2023
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.

Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki …

Cancer science, 114(8) 3461-3465, May 26, 2023
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.

Tomoki Naoe, Akiko Saito, Nahoko Hosono, Senji Kasahara, Hideharu Muto, Kaoru Hatano, Mizuki Ogura, Taro Masunari, Masatsugu Tanaka, Kensuke Usuki …

Cancer immunology, immunotherapy : CII, 1-7, Apr 24, 2023
Neuroendocrine neoplasms of the breast: diagnostic confusion and future perspectives.

Tomonori Kawasaki, Tomoaki Tashima, Atsushi Enomoto, Tetsuo Kondo, Hirokazu Nagai, Yasuhiro Nakamura, Jiro Ichikawa, Kiyomi Taniyama, Kyoichi Kaira

Virchows Archiv : an international journal of pathology, 482(5) 929-930, Mar 2, 2023 Peer-reviewed
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.

Hiroshi Hamada, Masaki Futamura, Hiroto Ito, Ryoko Yamamoto, Kenji Yata, Yasumasa Iwatani, Hirotaka Inoue, Noriaki Fukatsu, Hirokazu Nagai, Yoshinori Hasegawa

Vaccine, Feb 1, 2023
Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of an Asian Phase 2 Study.

Won-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, Kazuhito Yamamoto, Toshiki Uchida, Eiju Negoro, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando …

Blood advances, Jan 20, 2023
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study

Hideki Goto, Koji Izutsu, Daisuke Ennishi, Yuko Mishima, Shinichi Makita, Koji Kato, Miyoko Hanaya, Satoshi Hirano, Kazuya Narushima, Takanori Teshima …

INTERNATIONAL JOURNAL OF HEMATOLOGY, 116(6) 911-921, Dec, 2022
Neuroendocrine tumor of the breast showing invasive micropapillary features and multiple lymph node metastases

Tomonori Kawasaki, Tomoaki Tashima, Chisako Muramatsu, Akihiro Fujimoto, Yoko Usami, Hitomi Kodama, Jiro Ichikawa, Hirokazu Nagai, Kiyomi Taniyama

CANCER REPORTS, e1775, Dec, 2022
Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911, B-DASH study)

Tomotaka Suzuki, Mitsumi Terada, Ryunosuke Machida, Tomoko Kataoka, Yuta Ito, Keisuke Kataoka, Dai Maruyama, Hirokazu Nagai, Lymphoma Study Grp, Japan Clinical Oncology Grp

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Dec, 2022
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

Tomotaka Suzuki, Dai Maruyama, Ryunosuke Machida, Tomoko Kataoka, Noriyasu Fukushima, Nobuyuki Takayama, Rie Ohba, Ken Omachi, Yoshitaka Imaizumi, Masahito Tokunaga …

HEMATOLOGICAL ONCOLOGY, Nov, 2022
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.

Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Masahiro Yokoyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando …

Haematologica, 108(3) 811-821, Oct 6, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma.

Satsuki Murakami, Masaki Ri, Masato Ito, Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Yuichiro Inagaki, Junya Kuroda, Makoto Yoshimitsu, Akinao Okamoto …

International journal of hematology, 116(4) 563-569, Oct, 2022
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.

Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, Hirokazu Nagai, Shinichi Makita, Kenjiro Kamezaki, Toshiki Uchida, Shigeru Kusumoto, Junya Kuroda, Chisako Iriyama …

International journal of hematology, 117(1) 100-109, Sep 29, 2022
Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.

Tomotaka Suzuki, Dai Maruyama, Shinsuke Iida, Hirokazu Nagai

Japanese journal of clinical oncology, 52(9) 966-974, Sep 18, 2022
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Dai Maruyama, Shinsuke Iida, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto …

Cancer science, 113(9) 3267-3270, Jul 31, 2022
A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

Kenichi Ishizawa, Masahiro Yokoyama, Harumi Kato, Kazuhito Yamamoto, Masanori Makita, Kiyoshi Ando, Yasunori Ueda, Yoshimichi Tachikawa, Youko Suehiro, Mitsutoshi Kurosawa …

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 90(1) 83-95, Jul, 2022
Oral Kaposi sarcoma following cord blood transplantation.

Nobuhiko Imahashi, Mikiko Arakawa, Akari Iwakoshi, Mikiko Mori, Hirokazu Nagai, Hiroatsu Iida

EJHaem, 3(2) 569-570, May, 2022
Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial

Tsutomu Kobayashi, Kazuhito Yamamoto, Yoshitoyo Kagami, Ryunosuke Machida, Kana Miyazaki, Shigeo Nakamura, Junya Kuroda, Dai Maruyama, Hirokazu Nagai

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 52(6) 583-588, May, 2022
Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia

Shinobu Tsuzuki, Takahiko Yasuda, Masahito Kawazu, Toshihide Ueno, Sivasundaram Karnan, Akinobu Ota, Masashi Sanada, Hirokazu Nagai, Akihiro Tomita, Yoshiyuki Takahashi …

CANCER SCIENCE, 113 1236-1236, Feb, 2022

Misc.

Copy Number Alterations of Chromosome 9p24.1 in Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received ABVD: An Ancillary Analysis of Multi-Center Retrospective Study in Japan (HORIZON study)

Shinichi Makita, Shigeru Kusumoto, Jun-Ichi Tamaru, Hiroya Hashimoto, Akiko Miyagi Maeshima, Toshiki Uchida, Hideki Tsujimura, Eiichi Ohtsuka, Nobuyuki Takayama, Kayoko Murayama …

BLOOD, 140 11890-11892, Nov, 2022
Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando …

BLOOD, 140 3615-3617, Nov, 2022
ボルテゾミブの有害事象に関わるバイオマーカー候補HLAアリルの探索

亀位涼, 中嶋琢人, 坂部彩, 頭金正博, 李政樹, 飯田真介, 丸山大, 大佐賀智, 福原規子, 宮崎香奈 …

臨床薬理, 51(Suppl.) S301-S301, Oct, 2020
High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura.

Ken Takase, Hirokazu Nagai, Moe Kadono, Takanori Yoshioka, Nobuyuki Yoshio, Yukio Hirabayashi, Takuo Ito, Morio Sawamura, Akihiro Yokoyama, Shinichiro Yoshida …

International journal of hematology, 111(3) 388-395, Mar, 2020
Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki …

BLOOD, 132, Nov, 2018
再発または難治性の日本人低悪性度B細胞リンパ腫患者に対するコパンリシブの第Ib相試験(Phase Ib study of copanlisib in Japanese patients with relapsed/refractory indolent B-cell lymphoma)

福原規子, 丸山大, 畠清彦, 永井宏和, 亀崎健次郎, 小坂さおり, 飛内賢正

臨床血液, 59(9) 1502-1502, Sep, 2018
大量化療前導入治療R-CHOP-14とR-CHOP-14/CHASERの比較試験 JCOG0908(R-CHOP-14 vs. R-CHOP-14/CHASER induction prior to HDT in poor-risk untreated DLBCL: JCOG0908)

丸山大, 鏡味良豊, 柴田大朗, 飛内賢正, 山本一仁, 今泉芳孝, 内田俊樹, 島田和之, 皆内康一郎, 福原規子 …

臨床血液, 59(9) 1556-1556, Sep, 2018
未治療移植非適応多発性骨髄腫に対するMPB療法変法のランダム化第II相試験(JCOG 1105)(Randomized phase II study to optimize MPB in untreated transplant-ineligible myeloma: JCOG1105)

飯田真介, 丸山大, 小川岳人, 楠本茂, 福原傑, 福原規子, 瀬尾幸子, 宮崎香奈, 吉満誠, 黒田純也 …

臨床血液, 59(9) 1610-1610, Sep, 2018
A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)

K. Yamamoto, K. Hatake, N. Fukuhara, S. Kusumoto, H. Nagai, Y. Kobayashi, T. Kakihara, M. Shintani, A. Roberts, P. Maciag …

HAEMATOLOGICA, 102 468-468, Jun, 2017
Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Yoshinobu Maeda, Kensei Tobinai, Hirokazu Nagai, Takahiko Nakane, Tatsu Shimoyama, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, Koji Izutsu, Ryuzo Ueda

BLOOD, 128(22), Dec, 2016
The efficacy and safety of re-administration of rasburicase for patients with hematological malignancies

Kyoko Imamura, Keiji Sugiyama, Yuta Hasegawa, Hiroyuki Nakamura, Yasuhiro Suzuki, Takashi Tokunaga, Yasuhiko Miyata, Akane Kunitomi, Hiroatsu Iida, Hirokazu Nagai

ANNALS OF ONCOLOGY, 27, Jul, 2016
MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA

I. Yoshida, A. M. Saito, S. Tanaka, I. Choi, M. Hidaka, Y. Miyata, Y. Inoue, S. Yamasaki, T. Kagoo, H. Iida …

HAEMATOLOGICA, 101 128-129, Jun, 2016
Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL).

Kunihiro Tsukasaki, Kensei Tobinai, Toshiki Uchida, Yoshinobu Maeda, Hirohiko Shibayama, Hirokazu Nagai, Mitsutoshi Kurosawa, Yasunobu Abe, Kiyohiko Hatake, Kiyoshi Ando …

JOURNAL OF CLINICAL ONCOLOGY, 34(15), May, 2016
HIV関連悪性リンパ腫治療の手引きVer3.0

味澤篤, 永井宏和, 小田原隆, 上平朝子, 四本美保子, 萩原將太郎, 田沼順子, 岡田誠治, HIV感染症に合併するリンパ腫発症危険因子の探索と治療法確立に向けた全国規模多施設共同研究の展開, 研究班

日本エイズ学会誌, 18(1) 92-104, Feb, 2016
Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Won-Seog Kim, Michinori Ogura, Toshiki Uchida, Naokuni Uike, Yasunobu Abe, Kenichi Ishizawa, Yoko Okitsu, Kensei Tobinai, Fumiko Nagahama, Yusuke Sonehara …

BLOOD, 126(23), Dec, 2015
The efficacy and safety of gemcitabine, dexamethasone, and cisplatine (GDP) therapy for relapsed/refractory lymphoma

Kazuki Nozawa, Keiji Sugiyama, Yuta Hasegawa, Hiroyuki Nakamura, Daiki Hirano, Takashi Tokunaga, Yasuhiko Miyata, Akane Kunitomi, Hiroatsu Ida, Hirokazu Nagai

ANNALS OF ONCOLOGY, 26 147-148, Nov, 2015
Long-term follow up of AIDS-related primary central nervous system lymphoma in the cART era.

Keiji Sugiyama, Yuki Kojima, Hirokazu Nagai, Takashi Odawara, Mihoko Yotsumoto, Atsushi Ajisawa, Shotaro Hagiwara, Tomoko Uehira, Toshikazu Miyakawa, Hidetoshi Igari …

JOURNAL OF CLINICAL ONCOLOGY, 33(15), May, 2015
HIV感染者に合併した肺がんの多施設調査

大熊裕介, 味澤篤, 田沼順子, 竹田雄一郎, 大寺博, 上平朝子, 小島勇貴, 永井宏和, 四本美保子, 瀬戸口靖弘 …

日本呼吸器学会誌, 4(増刊) 168-168, Mar, 2015
Recent advances in Hodgkin lymphoma: Interim PET and molecular-targeted therapy

Hirokazu Nagai

Japanese Journal of Clinical Oncology, 45(2) 137-145, Feb 1, 2015
Combination of the Histone Deacetylase Inhibitor Vorinostat with a B-Cell Receptor Signaling Inhibitor Markedly Decreases Cyclin D1 Expression in a Mantle Cell Lymphoma Cell Line

Kazumi Hagiwara, Hiroatsu Iida, Yasuhiko Miyata, Tomoki Naoe, Hirokazu Nagai

BLOOD, 124(21), Dec, 2014

Research Projects

Comparative effectiveness research in first-line therapies for untreated multiple myeloma

Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Japan Society for the Promotion of Science, 2011 - 2012

TERASAWA Teruhiko, NAGAI Hirokazu
p57KIP2 methylation as a prognostic biomarker of malignant lymphoma

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, 2010 - 2012

NAGAI Hirokazu
The analysis of p57KIP2 gene in hematologic malignancies

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, 2007 - 2008
Analysis of p57KIP2 gene as tumor suppressor gene

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, 2004 - 2005

NAGAI Hirokazu

Profile Information

Research Interests

Research Areas

Research History

Education

Papers

Misc.

Research Projects

Menu

Coauthors